Equities

Shanghai ZJ Bio-Tech Co Ltd

688317:SHH

Shanghai ZJ Bio-Tech Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (CNY)17.83
  • Today's Change-0.43 / -2.35%
  • Shares traded1.78m
  • 1 Year change-23.15%
  • Beta--
Data delayed at least 15 minutes, as of Nov 15 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Shanghai ZJ Bio-Tech Co Ltd's revenues fell -88.21% from 2.33bn to 274.33m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a gain of 760.27m to a loss of 136.86m.
Gross margin68.92%
Net profit margin-89.26%
Operating margin-102.60%
Return on assets-4.52%
Return on equity-4.75%
Return on investment-4.74%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at Shanghai ZJ Bio-Tech Co Ltd fell by 378.19m. Cash Flow from Investing was negative at 77.69m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 81.88m for operations while cash used for financing totalled 234.39m.
Cash flow per share--
Price/Cash flow per share--
Book value per share19.64
Tangible book value per share19.58
More ▼

Balance sheet in CNYView more

Shanghai ZJ Bio-Tech Co Ltd appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio19.89
Quick ratio18.50
Total debt/total equity0.0014
Total debt/total capital0.0014
More ▼

Growth rates in CNY

Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -100.00% and -118.12%, respectively.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
-218.69
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.